Great to present phase 1b data for DLL3 ADC ZL-1310 (zoci) in platinum-refractory neuroendocrine carcinomas at #AACR26. Phase 2 is ongoing and we are excited to develop this drug further for these difficult to treat populations. @ZaiLab_Global @MSKCancerCenter @MSK_DeptOfMed https://t.co/oZzAU4ndpi